Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2011-02-01
2011-02-01
Krass, Frederick (Department: 1612)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
C514S023000, C514S546000, C514S558000
Reexamination Certificate
active
07879908
ABSTRACT:
The use of L-carnitine, or one of its pharmaceutically acceptable salts, is described in combination with glucose for the preparation of a medicament useful for diminishing the number of deaths caused by acute myocardial infarction, for reducing the number of days infarction patients spend in intensive care in hospital, and for reducing the number of episodes of post-infarction heart failure, in which the L-carnitine is administered intravenously within only a few hours of the onset of symptoms of acute myocardial infarction at an initial dose of 9 grams a day in combination with 1000-1500 mL of a 5% glucose solution for 5 days, after which the L-carnitine treatment is continued at a dose of 4 grams a day administered orally.
REFERENCES:
patent: 4320145 (1982-03-01), Cavazza et al.
patent: 6221851 (2001-04-01), Feldman
patent: 2002/0002202 (2002-01-01), Cavazza et al.
patent: 0 627 161 (1994-12-01), None
patent: 01/26649 (2001-04-01), None
patent: 2004/091602 (2004-10-01), None
Iliceto et al., “Effects of L-Carnitine Administration on Left Ventricular Remodeling After Acute Anterior Myocardial Infarction: The CEDIM trial.” Journal of the American College of Cardiology 1995: 26(2);380-387.
Arsenian et al.,Safety, tolerability, and efficacy of a glucose-insulin-potassium-magnesium-carnitine solution in acute myocardial infarction, American Journal of Cardiolgy , vol. 78, No. 4, 1996, pp. 476-479, XP002373680.
Grandi et al.,Effect of acute carnitine administration on glucose insulin metabolism in healthy subjects, International Journal of Clinical Pharmacology Research, vol. 17, No. 4, 1997, pp. 143-147, XP008061830.
Pfeffer et al, Circulation, 1990; 81; 1161-1172.
Walker, “Role of Vital Statistics in Medical Science,” read before the Vital Statistics Section of the American Public Health Association at the Sixty-fifth Annual Meeting in New Orleans, La., Oct. 20, 1936.
Junyou, C. et al. “Observation of Effect of Clinic Treatment of AMI Using L-carnitine in Early Stages” Jiangsu Journal of Clinical Medicine, vol. 3, No. 4, pp. 331-332, Dec. 31, 1999.
Krass Frederick
Lucas & Mercanti LLP
Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
Webb Walter E
LandOfFree
Use of L-carnitine for the treatment of cardiovascular diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of L-carnitine for the treatment of cardiovascular diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of L-carnitine for the treatment of cardiovascular diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2637154